Can you measure bone lesions with RECIST 1.1

Can you measure bone lesions with RECIST 1.1

This is a short overview of how to use Anderson criteria as modification to RECIST 1.1 to measure bone lesions. The criteria was developed by The University of Texas MD Anderson Cancer Center back in 2004 and is gaining popularity in clinical research because it allows patient who would be considered as not having measurable disease per RECIST 1.1 to be included in clinical trials.
You can learn more about this criteria here: Cancer Response Criteria and Bone Metastases: RECIST 1.1, MDA and PERCIST

 

  0 likes
Please follow and like us:
Video review: RECIST 1.1 vs Choi Criteria

Video review: RECIST 1.1 vs Choi Criteria

While RECIST 1.1 is the most popular criteria for solid tumour evaluation, little is known among clinical trials teams in hospitals about another criteria – Choi criteria – which has shown to be very accurate and in some cases even better option. In this video review we have compared RECIST 1.1 and Choi criteria in order to provide research teams with more information regarding this criteria which is gaining popularity in oncology clinical trials.
  0 likes
Please follow and like us:
Video review: Why do I need CRF access

Video review: Why do I need CRF access

This is another short guide for health care professionals, which is explaining one of the most used systems in clinical trials – Case Report Form (CRF). The purpose of our video is to explain to physicians that are not experienced in clinical trials why they need access to the system.
  0 likes
Please follow and like us: